Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice.
Tofogliflozin,一種鈉葡萄糖共轉運輸蛋白2抑制劑,改善小鼠左心病所致的肺血管重塑。
J Cardiol 2023-04-06
Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy.
Empagliflozin透過在5/6腎切除大鼠中促進替代性巨噬細胞活化,降低腎纖維化並改善腎功能。
Biomed Pharmacother 2022-11-23
SGLT2i Alleviates Atherosclerosis by Inhibiting NHE1 Activation to Protect against Macrophage Senescence Induced by Angiotensin II.
SGLT2i通過抑制NHE1活化來緩解動脈粥樣硬化,以保護免受由Angiotensin II誘導的巨噬細胞衰老。
Comb Chem High Throughput Screen 2024-05-28
SGLT2 抑制劑有助於對抗動脈硬化,研究指出達帕格列醇可減少老化細胞及斑塊,改善細胞活性,並降低血管緊張素 II 引起的巨噬細胞老化。此外,達帕格列醇也能降低 NHE1 和 SGLT2 的表達,緩解動脈硬化,保護巨噬細胞不受血管緊張素 II 影響。總結來說,SGLT2 抑制劑對於保護血管健康有正面效果。
PubMedDOI
Empagliflozin attenuates epithelial to mesenchymal transition through senescence in peritoneal dialysis.
Empagliflozin透過衰老在腹膜透析中減緩上皮向間質轉變。
Am J Physiol Renal Physiol 2024-07-04
Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy?
使用二肽基肽酶-4抑制劑調節巨噬細胞:治療糖尿病性心肌病的新前沿?
World J Diabetes 2024-09-16